• Antibacterial Drug Use and Resistance in Psychiatric Hospita

  2026-05-27

  This study provides a detailed, data-driven account of antibacterial drug use patterns and bacterial resistance in a psychiatric hospital during the 2022 COVID-19 epidemic. It reveals both rational antibiotic stewardship and emerging resistance challenges, especially concerning third-generation cephalosporins like cefodizime, offering critical guidance for infection control in similar clinical environments.

• Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio

  2026-05-27

  This study reveals that murine norovirus co-opts the cell death regulator NINJ1 to specifically secrete the viral NS1 protein, distinguishing this process from bulk DAMP release during apoptosis. The findings redefine our understanding of how viruses exploit programmed cell death machinery for selective protein export, with implications for both virology and regulated cell death research.

• Optimizing Macrophage Gene Delivery with EZ Cap™ Cy5 EGFP mR

  2026-05-26

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) advances macrophage-targeted gene delivery. We uncover unique insights into nanoparticle-mediated transfection and real-time dual-fluorescent tracking, extending beyond standard translation assays.

• MHY1485 in Metabolic Research: mTOR Activation Beyond Oncolo

  2026-05-26

  Explore how MHY1485, a potent mTOR activator, is reshaping metabolic and autophagy research. This article uniquely examines its applications in lipid metabolism and ovarian follicle development, offering insights not found in previous content.

• TBXA2R Drives ERM Activation and Metastasis in TNBC Cells

  2026-05-25

  This study uncovers how the thromboxane A2 receptor (TBXA2R) activates ERM proteins, promoting motility, invasion, and metastatic colonization in triple-negative breast cancer (TNBC) cells. The results reveal a novel GPCR-driven pathway for ERM activation, highlighting new therapeutic targets for metastatic cancer intervention.

• Alosetron and 5-HT3 Antagonism: Advancing GI Stem Cell Resea

  2026-05-25

  Explore how Alosetron, a selective 5-HT3 receptor antagonist, is shaping the next era of gastrointestinal stem cell research. This article blends mechanistic insight into serotonin signaling, epithelial polarity, and the Hippo-YAP-mTOR pathway with actionable strategies for translational investigators. By bridging foundational studies with advanced protocols, we highlight how APExBIO’s Alosetron is redefining experimental rigor and opening new frontiers in gut biology.

• Triacetin (SKU BA1710): Reliable Solutions for Cell-Based As

  2026-05-24

  This article provides scenario-driven, evidence-based guidance for researchers using Triacetin (SKU BA1710) in cell viability, proliferation, and cytotoxicity assays. Grounded in peer-reviewed data and real-world laboratory challenges, it demonstrates how Triacetin’s chemical stability, mechanistic versatility, and validated safety profile—supported by APExBIO—enable reproducible and sensitive results across diverse workflows.

• Antibody Targeting of SCUBE3 Suppresses Oncogenic Signaling

  2026-05-23

  This study identifies secretory SCUBE3 as a critical driver of tumor growth, therapy resistance, and immunosuppression across multiple cancer types. Using a first-in-class neutralizing antibody, the research demonstrates suppression of oncogenic signaling and restoration of antitumor immunity, highlighting SCUBE3 as a promising therapeutic target.

• Indomethacin Sodium Trihydrate: COX Inhibition and Beyond

  2026-05-22

  Indomethacin Sodium Trihydrate, a nonsteroidal anti-inflammatory drug, acts via non-selective COX-1/COX-2 inhibition and Wnt/β-catenin pathway modulation. Its trihydrated sodium salt form offers high solubility and reproducible outcomes in inflammation assay and neuroregeneration models. Evidence supports its utility in both in vitro and in vivo contexts for anti-inflammatory research.

• MOF-Based mRNA Encapsulation: Advances in Delivery and Stabi

  2026-05-22

  This study introduces the first robust methodology for encapsulating and delivering messenger RNA (mRNA) using nanoscale metal-organic frameworks (MOFs), specifically ZIF-8, featuring stability in biological media and prolonged storage at room temperature. The findings demonstrate MOF-mRNA complexes achieve effective gene expression in vitro and in vivo, establishing a new platform for non-viral mRNA delivery and storage.

• Light-Inducible RNA Switches Enable Precise Gene Therapy Con

  2026-05-21

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that enables optogenetic, translation-level regulation of therapeutic gene expression in vivo. This innovation allows precise, tissue-specific, and reversible gene therapy interventions, with direct implications for chronic metabolic and retinal diseases.

• Cell Counting Kit-8 (CCK-8): Sensitive Cell Viability Quanti

  2026-05-21

  The Cell Counting Kit-8 (CCK-8) enables precise, water-soluble tetrazolium salt-based cell viability measurement. CCK-8 provides a sensitive, rapid, and user-friendly alternative to older cell proliferation and cytotoxicity assays, facilitating reliable quantification in cancer research and beyond.

• Mitomycin C in Cancer Research: Applied Workflows & Optimiza

  2026-05-20

  Mitomycin C stands apart as an antitumor antibiotic, combining potent DNA crosslinking with robust apoptosis pathway modulation. This guide details advanced workflows, troubleshooting, and protocol enhancements to maximize assay fidelity in apoptosis signaling and cancer research.

• TAI-1: Precision Hec1 Inhibition for Tumor Suppressor-Driven

  2026-05-20

  Explore TAI-1, a first-in-class Hec1 inhibitor, and its unparalleled potency in apoptotic cell death induction and cancer cell proliferation inhibition. This article uniquely connects TAI-1’s mechanism to tumor suppressor gene status and practical assay design, integrating the latest organoid insights for translational research.

• VX-745 in Precision p38α MAPK Inhibition: Mechanistic Advanc

  2026-05-19

  Discover how VX-745, a potent p38α MAPK inhibitor, is transforming research on inflammation and drug resistance. This article delivers a deep mechanistic analysis, practical assay guidance, and fresh insights distinct from conventional VX-745 overviews.

14985 records 1/999 page Next 12345 下5页 Last page